In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.
Procedure: Questionnaire
At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
Other: Data collection up to 1 year
Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
Inclusion Criteria:
- Ocular pathology requiring repeated IVT treatment of anti-angiogenic drugs (exudative
AMD, diabetic macular edema or secondary to retinal venous occlusion ...)
- Beginning of IVT treatment repeated before 10/01/2019 (6 months before the start of
French confinement)
Exclusion Criteria:
- Refusal to participate
Centre Pôle Vision du val d'Ouest
Ecully, France
Fondation Adolphe de Rothschild
Paris, France
Hôpital Lariboisière
Paris, France
Centre ophtalmologique Maison Rouge
Strasbourg, France
Martine MAUGET FAYSSE, MD, Principal Investigator
Fondation Adolphe de Rothschild